Figure 1. Precision medicine in kidney disease. The signalosome of ANG3070, an orally bioavailable
small molecule fibrokinase inhibitor is depicted within the blue circle. The red hotspots indicate
signaling elements modulated by this drug candidate. A precision medicine approach is being used
to inform inclusion criteria for an ANG 3070 clinical trial in nephrotic syndrome- focal segmental
glomerulosclerosis (NS-FSGS). Renal biopsy and urinalysis from these patients will be subjected to
omics analysis and signalosomes (green circle) identified for each patient. Only those patients will be
recruited that share 70% of the ANG3070 signaling elements.
